-
公开(公告)号:US20210308126A1
公开(公告)日:2021-10-07
申请号:US16949571
申请日:2020-11-04
发明人: Tetsuro Kikuchi , Taro Iwamoto , Tsuyoshi Hirose
IPC分类号: A61K31/496 , A61K31/19 , A61K31/195 , A61K31/425 , A61K31/4704 , A61K31/497 , A61K31/55 , A61K31/7008 , A61K33/00 , A61K33/14 , A61K45/06 , A61K31/357 , A61K31/4015 , A61K31/423 , A61K31/53 , A61K31/5513
摘要: The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbemazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, manta or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.
-
12.
公开(公告)号:US20200289501A1
公开(公告)日:2020-09-17
申请号:US16664984
申请日:2019-10-28
发明人: Tetsuro Kikuchi , Taro Iwamoto , Tsuyoshi Hirose
IPC分类号: A61K31/496 , A61K31/135 , A61K31/15 , A61K31/165 , A61K31/343 , A61K31/381 , A61K31/4525 , A61K31/137 , A61K31/138 , A61P25/28 , A61P25/18 , A61P25/24
摘要: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
-
13.
公开(公告)号:US20190151308A1
公开(公告)日:2019-05-23
申请号:US16242315
申请日:2019-01-08
发明人: Tetsuro Kikuchi , Taro Iwamoto , Tsuyoshi Hirose
IPC分类号: A61K31/496 , A61K31/343 , A61P25/18 , A61P25/24 , A61P25/28
摘要: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
-
公开(公告)号:US20170224681A1
公开(公告)日:2017-08-10
申请号:US15494877
申请日:2017-04-24
IPC分类号: A61K31/496
CPC分类号: A61K31/496 , A61K31/4704 , A61K45/06 , A61K2300/00
摘要: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
-
公开(公告)号:US09006248B2
公开(公告)日:2015-04-14
申请号:US13932385
申请日:2013-07-01
IPC分类号: A61K31/497 , C07D401/00 , A61K31/496 , A61K45/06
CPC分类号: A61K31/496 , A61K31/4704 , A61K45/06 , A61K2300/00
摘要: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1): wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
摘要翻译: 本发明涉及一种治疗患有与5-HT 1A受体亚型相关的中枢神经系统紊乱的患者的方法,其包含由式(1)表示的喹诺酮衍生物或其盐作为活性成分:其中, 喹诺酮骨架中3-和4-位之间的碳 - 碳键是单键或双键。
-
-
-
-